Discontinuation of immunosuppressive antimetabolite for parvovirus B19-associated anemia in kidney transplant patients.
Shimmura
H
H
Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.
Tanabe
K
K
Ishikawa
N
N
Tokumoto
T
T
Toda
F
F
Toma
H
H
D000328:Adult; D000740:Anemia / Q000628:therapy / Q000821:virology*; D000914:Antibodies, Viral / Q000097:blood; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use*; D001854:Bone Marrow Cells / Q000473:pathology; D004279:DNA, Viral / Q000097:blood; D004359:Drug Therapy, Combination; D017707:Erythrocyte Transfusion; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007676:Kidney Failure, Chronic / Q000601:surgery; D016030:Kidney Transplantation / Q000276:immunology*; D008297:Male; D009173:Mycophenolic Acid / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D010322:Parvoviridae Infections / Q000150:complications* / Q000175:diagnosis; D016732:Parvovirus B19, Human; D016133:Polymerase Chain Reaction; D011183:Postoperative Complications / Q000821:virology*; D017701:Reticulocyte Count
D000914:Antibodies, Viral; D004279:DNA, Viral; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid; D001379:Azathioprine